Cargando…

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

BACKGROUND: Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival on EGFR TKI treatment is between 12 and 14 months. However, some patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalens, Lorraine, Niogret, Julie, Richard, Corentin, Chevrier, Sandy, Foucher, Pascal, Coudert, Bruno, Lagrange, Aurélie, Favier, Laure, Westeel, Virginie, Kim, Stefano, Adotevi, Olivier, Chapusot, Caroline, Martin, Laurent, Arnould, Laurent, Kaderbhai, Courèche-Guillaume, Boidot, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385908/ https://www.ncbi.nlm.nih.gov/pubmed/37516818 http://dx.doi.org/10.1186/s12943-023-01829-4

Ejemplares similares

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life
por: Dalens, Lorraine, et al.
Publicado: (2022)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
por: Tankere, Pierre, et al.
Publicado: (2022)

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
por: Chevrier, Sandy, et al.
Publicado: (2021)

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022)

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2018)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
por: Schmitt, Esther, et al.
Publicado: (2015)

Small Cell Neuroendocrine Carcinoma of the Paranasal Sinuses with Unexpected Location and Clinical Presentation and Occupational Exposure: A Case Report
por: Tankere, Pierre, et al.
Publicado: (2022)

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
por: Réda, Manon, et al.
Publicado: (2023)

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)

Implementation and use of whole exome sequencing for metastatic solid cancer
por: Réda, Manon, et al.
Publicado: (2020)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Kaderbhaï, Courèche, et al.
Publicado: (2019)

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study
por: Ladoire, Sylvain, et al.
Publicado: (2021)

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study
por: Ladoire, Sylvain, et al.
Publicado: (2022)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use
por: Chevrier, Sandy, et al.
Publicado: (2022)

Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma
por: Végran, Frédérique, et al.
Publicado: (2013)

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
por: Végran, F, et al.
Publicado: (2009)

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
por: Dosset, Magalie, et al.
Publicado: (2018)

Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients
por: Mazel, Benoit, et al.
Publicado: (2023)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

Transcriptome-wide identification of transient RNA G-quadruplexes in human cells
por: Yang, Sunny Y., et al.
Publicado: (2018)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
por: Royer, Bernard, et al.
Publicado: (2021)

Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization
por: Courtaut, Flavie, et al.
Publicado: (2015)

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
por: Eliade, Marie, et al.
Publicado: (2016)

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
por: Ledys, Fanny, et al.
Publicado: (2018)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study
por: Chanteloup, Gaëtan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u8rh8kndnvj957tukd12phrnvd